Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARBUNCLE study of dose-dense MVACarbo in cisplatin-ineligible advanced urothelial cancer
jRCTs051240026Recruiting
- Sponsor
- Nara Medical University
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of methotrexate, vinblastine, doxorubicin and carboplatin in transitional cell carcinoma (TCC), bladder cancer, renal pelvis cancer and 2 more, sponsored by Nara Medical University. Primary endpoint: Objective response rate. Started Jun 2024; status: recruiting.
02
Drugs
methotrexatevinblastinedoxorubicincarboplatin
03
Conditions
transitional cell carcinoma (TCC)bladder cancerrenal pelvis cancerureteral cancerurethral cancer
Beyond the preview
Go deeper on jRCTs051240026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240026.